Indian Journal of Pathology and Microbiology
Home About us Instructions Submission Subscribe Advertise Contact e-Alerts Ahead Of Print Login 
Users Online: 426
Print this page  Email this page Bookmark this page Small font sizeDefault font sizeIncrease font size

Year : 2008  |  Volume : 51  |  Issue : 1  |  Page : 139-142
Prevalence of extended-spectrum β-lactamases among Escherichia coli and Klebsiella pneumoniae isolates in a tertiary care hospital

Department of Microbiology, Armed Forces Medical College, Pune, India

Click here for correspondence address and email


Extended-spectrum β-lactamases (ESBLs) continue to be a major problem in clinical setups the world over, conferring resistance to the expanded-spectrum cephalosporins. Knowledge about their prevalence is essential to guide towards appropriate antibiotic treatment. The aim of the present study is to determine the prevalence of ESBL producers among Escherichia coli and Klebsiella pneumoniae isolates at a tertiary care institution. A total of 357 clinical isolates comprising E. coli (n = 181) and K. pneumoniae (n = 176) were recovered from various clinical samples over a period of six months from April to September 2006. Antibiogram profile of these isolates was determined to commonly used antibiotics, along with screening for ESBL production by the screening test as recommended by the Clinical Laboratory Standards Institute (CLSI). Isolates which showed positive results with screening test were shortlisted for confirmatory tests of ESBL production. Two tests were performed: phenotypic confirmatory test with combination disk and the minimum inhibitory concentration (MIC) reduction test.
Out of 357 isolates of E. coli and K. pneumoniae screened for ESBL production, 120 were found to be potential ESBL producers. Of these, 80 isolates were confirmed to be ESBL producers. Thus the prevalence of ESBL-producing isolates of E. coli and K. pneumoniae was found to be 22% (80 out of 357). This was significantly lower than the data available from other hospitals.

Keywords: Escherichia coli, extended-spectrum β-lactamase, Klebsiella pneumoniae, third-generation cephalosporins

How to cite this article:
Agrawal P, Ghosh A N, Kumar S, Basu B, Kapila K. Prevalence of extended-spectrum β-lactamases among Escherichia coli and Klebsiella pneumoniae isolates in a tertiary care hospital. Indian J Pathol Microbiol 2008;51:139-42

How to cite this URL:
Agrawal P, Ghosh A N, Kumar S, Basu B, Kapila K. Prevalence of extended-spectrum β-lactamases among Escherichia coli and Klebsiella pneumoniae isolates in a tertiary care hospital. Indian J Pathol Microbiol [serial online] 2008 [cited 2022 Aug 19];51:139-42. Available from: https://www.ijpmonline.org/text.asp?2008/51/1/139/40428

   Introduction Top

Resistant bacteria are emerging worldwide as a threat to favorable outcome in the treatment of common infections in community and hospital settings. [1] Among the wide array of antibiotics, β-lactams are the most widely used agents. The most common cause of resistance to β-lactam antibiotics is the production of β-lactamases. Emergence of resistance to β-lactam antibiotics began even before the first β-lactam, penicillin, was developed. The first plasmid-mediated β-lactamase TEM-1 was originally isolated from blood culture of a patient named Temoniera in Greece, in the early 1960s. [2] TEM-1 being plasmid and transposon mediated has facilitated its spread to other species of bacteria. Another common plasmid-mediated β-lactamase is SHV-1 (sulfhydryl variable), which is chromosomally encoded in the majority of isolates of K. pneumoniae but is usually plasmid-mediated in E. coli . Over the years, many new β-lactam antibiotics have been developed; however, with each new class of antibiotic, a new β-lactamase emerged that caused resistance to that class of drug. Presumably, the selective pressure imposed by the use and overuse of new antibiotics in the treatment of patients has resulted in the emergence for new variants of β-lactamase.

The introduction of third-generation cephalosporins into clinical practice in the early 1980s was heralded as a major breakthrough in the fight against β-lactamase-mediated bacterial resistance to antibiotics. Soon after the introduction, the first report of plasmid-encoded β-lactamase capable of hydrolyzing the extended-spectrum cephalosporins was published in 1983 from Germany. [3] Hence these new β-lactamases were coined as extended-spectrum β-lactamases (ESBLs). The total number of ESBLs characterized exceeds 200 today. There is no consensus on the precise definition of ESBLs. A commonly used working definition is that the ESBLs are β-lactamases capable of conferring bacterial resistance to the penicillins; first-, second- and third-generation cephalosporins; and aztreonam (but not the cephamycins and carbapenems) by hydrolysis of these antibiotics and which are inhibited by β-lactamase inhibitors such as clavulanic acid. [4]

ESBLs are encoded by transferable conjugative plasmids which often code resistant determinants to other antibiotics. The plasmid-mediated resistance against cephalosporins can spread among related and unrelated gram-negative bacteria. ESBLs are mostly the products of point mutations at the active site of TEM and SHV enzymes. [5] Nosocomial outbreaks of infections caused by ESBL-producing gram-negative bacteria have also been reported, which are mainly the result of extensive and inappropriate use of third-generation cephalosporins. Majority of ESBL-producing organisms are E. coli and K. pneumoniae. Others include Enterobacter spp. ,  Salmonella More Details spp. , Morganella, Proteus mirabilis, Serratia marcescens, and Pseudomonas aeruginosa . The major risk factors implicated are long-term exposure to antibiotics, prolonged ICU stay, nursing home residency, severe illness, instrumentation, or catheterization. [6]

Since ESBL-positive isolates show false susceptibility to expanded-spectrum cephalosporins in standard disk diffusion test, it is difficult to reliably detect ESBL production by the routine disk diffusion techniques. Specific detection methods recommended by CLSI have to be adopted. ESBLs are specifically inhibited by β-lactamase inhibitors like clavulanic acid, and this property is utilized for the detection and confirmation of ESBLs. [7]

Prevalence of ESBLs varies from institute to institute. Previous studies from India have reported ESBL production varying from 6% to 87%. [8],[9],[10],[11],[12] Keeping in view the above facts, this study was undertaken to find the prevalence of ESBL producers among E. coli . and K. pneumoniae isolates at our institute. Moreover, the aim of this study was also to compare the antibiotic susceptibility pattern of ESBL producers with that of non-ESBL producers and to delineate the magnitude of the problem and to define appropriate therapeutic options.

   Materials and Methods Top

Clinical isolates

A total of 357 consecutive non-repeat culture isolates of  Escherichia More Details coli and Klebsiella pneumoniae were obtained from different clinical specimens such as urine, pus, blood, body fluids, etc., over a period of six months (April to September 2006). The isolates were identified on the basis of conventional microbiological procedures. [13]

Antimicrobial susceptibility test

Antimicrobial susceptibility was determined by Kirby-Bauer disk diffusion method as per CLSI recommendations. [14] Antimicrobial disks used were Ampicillin (10 µg), Amoxycillin-clavulanic acid (20/10 µg), Piperacillin (100 µg), Piperacillin-tazobactam (100/10 µg), Cephotaxime (30 µg), Ceftriaxone (30 µg), Ceftazidime (30 µg), Gentamicin (10 µg), Amikacin (30 µg), Netilmicin (30 µg), Tetracycline (30 µg), Ciprofloxacin (5 µg), Chloramphenicol (30 µg), Trimethoprim-sulfamethoxazole (1.25/23.75 µg), and Imipenem (10 µg).

Screening test for ESBLs

According to the CLSI guidelines, isolates showing inhibition zone size of ≤ 22 mm with Ceftazidime (30 µg), ≤ 25 mm with Ceftriaxone (30 µg), and ≤ 27 mm with Cefotaxime (30 µg) were identified as potential ESBL producers and shortlisted for confirmation of ESBL production [Figure - 1]

Confirmatory tests for ESBLs

The following two procedures were carried out in the present study as per CLSI guidelines:

  1. Phenotypic confirmatory test with combination disk: This test requires the use of a third-generation cephalosporin antibiotic disk alone and in combination with clavulanic acid. In this study, a disk of Ceftazidime (30µg) alone and a disk of Ceftazidime + Clavulanic acid (30 µg/10 µg) were used. Both the disks were placed at least 25 mm apart, center to center, on a lawn culture of the test isolate on Mueller Hinton Agar (MHA) plate and incubated overnight at 37°C. Difference in zone diameters with and without clavulanic acid was measured [Figure - 2].

    Interpretation: When there is an increase of ≥ 5 mm in inhibition zone diameter around combination disk of Ceftazidime + Clavulanic acid versus the inhibition zone diameter around Ceftazidime disk alone, it confirms ESBL production.

  2. MIC reduction test: The isolates positive with combination disk test were further confirmed for ESBL production by this test. Minimum inhibitory concentration of the isolates was determined by Broth dilution method. The values of range of concentration of antibiotics tested were as follows:

    Ceftazidime: 0.25 µg/mL to 128 µg/mL

    Ceftazidime-clavulanic acid: 0.25/4 µg/mL to 128/4 µg/mL

    Interpretation: A ≥ 3 two-fold decrease in MIC for Ceftazidime when tested in combination with clavulanic acid versus its MIC when tested alone indicates that the strain is an ESBL producer.

    Control strain used to validate susceptibility tests was E. coli ATCC 25922.

Statistical analysis

Chi-square test was used with appropriate correction for the observation. Where the cell frequency was less than five, Fisher exact test was applied to see the significance of difference between the resistance levels of various drugs in ESBL producer strains and non-ESBL producer strains using EPI 6 software. p ≤ 0.05 was considered significant.

   Results Top

A total of 357 isolates of E. coli ( n = 181) and K. pneumoniae ( n = 176) were recovered from different clinical specimens submitted for routine microbiological analysis from both indoor and outdoor patients of a tertiary care hospital during a six-month period. The number of potential ESBL producers shortlisted by screening test was 120 out of the total 357. All of them showed inhibition zone size of ≤ 22 mm with Ceftazidime during screening test. Confirmatory tests for ESBL production were performed on these 120 isolates.

Out of 120 isolates, 52 E. coli and 28 K. pneumoniae isolates were found to be ESBL producers by phenotypic confirmatory test with combination disk. This was further confirmed by MIC reduction test, and the results of both tests were in concordance [Table - 1].

Thus 30% (52/181) of E. coli and 16% (28/176) of K. pneumoniae isolates were found to be ESBL producers. Distribution of these ESBL-positive isolates was highest among urinary isolates, accounting for 70% of all isolates recovered [Table - 2].

Antimicrobial susceptibility pattern

The multidrug resistance was significantly higher among ESBL producers than in non-ESBL producers. ESBL producers were almost always resistant to Ampicillin and Piperacillin. However, all the isolates were sensitive to Imipenem. [Table - 3] shows the comparison of antibiotic resistance among ESBL producers and non-ESBL producers.

   Discussion Top

In the present study, the prevalence of ESBL producers was found to be 22% (80 out of 357) among E. coli and K. pneumoniae isolates collected over a period of six months. The overall prevalence of ESBL producers was found to vary greatly in different geographical areas and in different institutes. Previous studies from India have reported ESBL production varying from 6% to 87%. [8],[9],[10],[11],[12] One reason for such variability may be the very low number of samples studied. In recent years, a significant increase in ESBL producers was reported from USA, [15] Canada, [16] China, [17] and Italy. [18] A recent large survey of 1610 Escherichia coli and 785 Klebsiella pneumoniae isolates from 31 centers in 10 European countries found that the prevalence of ESBL in these organisms ranged from as low as 1.5% in Germany to as high as 39-47% in Russia, Poland, and Turkey. [19]

ESBLs have emerged due to selective pressure imposed by extensive use of antimicrobials, especially in intensive care units. Since ESBL-positive isolates show false susceptibility to expanded-spectrum cephalosporins in standard disk diffusion test, it is essential to adopt the specific detection methods recommended by CLSI. Though the phenotypic confirmatory tests are highly sensitive and specific, there are a number of instances when these tests may be falsely positive or negative. False-positives may occur if the isolate lacks ESBL but produces an excess of TEM-1 or SHV-1. On the other hand, isolates harboring both ESBLs and AmpC-type β-lactamases may result in false-negative results. The likely explanation is that AmpC-type β-lactamases resist inhibition by clavulanic acid; moreover, clavulanic acid induces high level AmpC production, thus preventing ESBL recognition. [2]

The isolates which have a positive phenotypic confirmatory test for ESBL production should be reported as resistant to all cephalosporins (except cephamycins, cefoxitin, and cefotetan) and aztreonam, regardless of the MIC of that particular cephalosporin. Penicillins are reported as resistant and β-lactam/β-lactamase inhibitor combinations are reported as susceptible if the zone diameters are within the appropriate range.

The present study shows higher antimicrobial resistance among ESBL producers than among non-ESBL producers [Table - 3]. Almost all the ESBL-positive isolates were found to be resistant to Ampicillin and sensitive to Imipenem, which again advocates the usage of carbapenem antibiotics as the therapeutic alternative to β-lactam antibiotics as indicated in many previous studies.

   Conclusion Top

The prevalence of ESBL producers at our institute was lower in comparison to the prevalence reported from other hospitals in India. Routine detection of ESBL-producing microorganisms is required to be done by each laboratory by the standard detection methods so as to control the spread of these infections and also to institute proper therapeutic strategies. Phenotypic confirmatory test using combination disk is simple and cost effective for the detection of ESBL production as it has shown 100% concordance with MIC reduction test. The control measures include judicious use of antibiotics, strict hand-hygiene protocols, and implementation of appropriate infection-control measures in the hospital, especially while treating high-risk patients.

Patients' report must state that the isolate is a suspected or proven ESBL producer and also include a note stating that ESBL production may predict therapeutic failure with penicillins, aztreonam, and all cephalosporins (except cephamycins), irrespective of their in vitro susceptibility.

Monitoring and judicious usage of extended-spectrum cephalosporins, periodic surveillance of antibiotic resistance patterns, and efforts to decrease empirical antibiotic therapy would go a long way in addressing some of the problems associated with ESBLs.

   References Top

1.Chaudhary U, Aggarwal R. Extended spectrum β lactamases (ESBL): An emerging threat to clinical therapeutics. Indian J Med Microbiol 2004;22:75-80.  Back to cited text no. 1    
2.Bradford PA. Extended spectrum β lactamases in 21 st century: Characterization, epidemiology and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51.  Back to cited text no. 2    
3.Shukla I, Tiwari R, Agrawal M. Prevalence of extended spectrum β lactamase producing Klebsiella pneumoniae in a tertiary care hospital. Indian J Med Microbiol 2004;22:87-91.  Back to cited text no. 3    
4.Paterson DL, Bonomo RA. Extended spectrum β lactamases: A clinical update. Clin Microbiol Rev 2005;18:657-86.  Back to cited text no. 4    
5.Duttaroy B, Mehta S. Extended spectrum β lactamases (ESBL) in clinical isolates of Klebsiella pneumoniae and Escherichia coli. Indian J Pathol Microbiol 2005;48:45-8.  Back to cited text no. 5    
6.Kumar MS, Lakshmi V, Rajagopalan R. Occurrence of extended spectrum β lactamases among enterobacteriaceae spp. isolated at a tertiary care institute. Indian J Med Microbiol 2006;24:208-11.  Back to cited text no. 6    
7.Menon T, Bindu D, Kumar CPG, Nalini S, Thirunarayan MA. Comparison of double disk and three dimentional methods to screen for ESBL producers in a tertiary care hospital. Indian J Med Microbiol 2006;24:117-20.  Back to cited text no. 7    
8.Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended spectrum β lactamase producing Gram negative bacteria in a tertiary care hospital. Indian J Med Res 2002;115:153-7.  Back to cited text no. 8    
9.Hansotia JB, Agarwal V, Pathak AA, Saoji AM. Extended spectrum β lactamase mediate resistance to third generation cephalosporins in Klebsiella pneumoneae in Nagpur, central India. Indian J Med Res 1997;105:160-5.  Back to cited text no. 9    
10.Manchanda V, Singh NP, Goyal R, Kumar A, Thukral SS. Phenotypic characteristics of clinical isolates of Klebsiella pneumoniae and evaluation of available techniques for detection of extended spectrum beta lactamases. Indian J Med Res 2005;122:330-7.  Back to cited text no. 10    
11.Tankhiwale SS, Jalgaonkar SV, Ahamad S, Hassani U. Evaluation of extended spectrum beta lactamase in urinary isolates. Indian J Med Res 2004;120:553-6.  Back to cited text no. 11    
12.Jain A, Roy I, Gupta MK, Kumar M, Agarwal SK. Prevalence of extended spectrum β-lactamase producing Gram negative bacteria in septicaemic neonates in a tertiary care hospital. J Med Microbiol 2003;52:421-5.  Back to cited text no. 12    
13.Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Win WC, editors. The enterobacteriaceae. In : Color atlas and textbook of diagnostic microbiology, 5 th ed. JB Lippincott Co: Philadelphia; 2006. p. 211-302.  Back to cited text no. 13    
14.Clinical Laboratory Standards Institute; Performance standards for antimicrobial disc susceptibility testing. 14 th Informational Supplement: 2004.   Back to cited text no. 14    
15.Saurina G, Quale GM, Manikal VM, Oydna E, Landman D. Antimicrobial resistance in enterobacteriaceaein Brooklyn NY: Epidemiology and relation to antibiotic usage patterns. J Antimicrob Chemother 2000;45:895-8.  Back to cited text no. 15    
16.Cordero L, Rau R, Taylor D, Avers LW. Enteric Gram negative bacilli blood stream infections: 17 years experience in a neonatal intensive care unit. Am J Infect Control 2004;32:189-95.  Back to cited text no. 16    
17.Xiong Z, Zzhu D, Zhang Y, Wang F. Extended spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates. Zhongua Yi Xue Za Zhi 2002;82:1476-9.  Back to cited text no. 17    
18.Luzzaro F, Mezzatesta M, Mugnaioli C, Perilli M, Stefani S, Amicosante G, et al. Trends in production of Extended Spectrum B-Lactamases among Enterobacteria of medical interest: Report of the second Italian nationwide survey. J Clin Microbiol 2006;44:1659-64.  Back to cited text no. 18    
19.Goosens H. MYSTIC programme: Summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis 2001;41:183-9.  Back to cited text no. 19    

Correspondence Address:
Parul Agrawal
Department of Microbiology, Armed Forces Medical College, Pune - 411 040
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0377-4929.40428

Rights and Permissions


  [Figure - 1], [Figure - 2]

  [Table - 1], [Table - 2], [Table - 3]

This article has been cited by
1 Antimicrobial Susceptibility Profile and Immune Response of Bacteria Isolated from Urinary Tract Infections
Sarah A. Yousef, M. Ohood
Current Research in Bacteriology. 2022; 15(1): 1
[Pubmed] | [DOI]
2 Prevalence of multidrug-resistant and extended-spectrum beta-lactamase producing Gram-negative isolates from clinical samples in a tertiary care hospital of Nepal
Aryatara Shilpakar, Mehraj Ansari, Kul Raj Rai, Ganesh Rai, Shiba Kumar Rai
Tropical Medicine and Health. 2021; 49(1)
[Pubmed] | [DOI]
3 Antimicrobial resistance pattern of bacterial isolates and genetic resistance determinants of carbapenemase producers in bloodstream infections
Lipika Jena, Bichitrananda Swain, Swati Jain
CHRISMED Journal of Health and Research. 2020; 7(1): 56
[Pubmed] | [DOI]
4 High prevalence of blaCMY AmpC beta-lactamase in ESBL co-producing Escherichia coli and Klebsiella spp. clinical isolates in the northeast of Iran
Kobra Salimiyan Rizi, Arman Mosavat, Masoud Youssefi, Saeid Amel Jamehdar, Kiarash Ghazvini, Hadi Safdari, Yousef Amini, Hadi Farsiani
Journal of Global Antimicrobial Resistance. 2020; 22: 477
[Pubmed] | [DOI]
5 The Antimicrobial Resistance Pattern of Klebsiella pneumonia Isolated from the Clinical Specimens in Duhok City in Kurdistan Region of Iraq
Ibrahim Abdulqader Naqid, Nawfal Rasheed Hussein, Amer A Balatay, Kurdistan Abdullah Saeed, Hiba A Ahmed
Journal of Kermanshah University of Medical Sciences. 2020; 24(2)
[Pubmed] | [DOI]
6 Determination of antibiotic resistance and minimum inhibitory concentration of meropenem and imipenem growth in Klebsiella strains isolated from urinary tract infection in Shahrekord educational hospitals
Farshad Kakian, Behnam Zamzad, Abolfazl Gholipour, Kiarash Zamanzad
Journal of Shahrekord University of Medical Sciences. 2019; 21(2): 80
[Pubmed] | [DOI]
7 Determination of the carbapenem resistance in Escherichia coli isolated from samples obtained from Shahrekord hospitals and determination of their minimum inhibitory concentration
Farshad Kakian, Behnam Zamanzad, Abolfazle Gholipour, Kiarash Zamanzad
Journal of Shahrekord University of Medical Sciences. 2019; 21(6): 280
[Pubmed] | [DOI]
8 Changing paradigm of antibiotic resistance amongst Escherichia coli isolates in Indian pediatric population
Taru Singh,Praveen Kumar Singh,Sajad Ahmad Dar,Shafiul Haque,Naseem Akhter,Shukla Das,Vijai Gupta
PLOS ONE. 2019; 14(4): e0213850
[Pubmed] | [DOI]
Ashok M. S, Deepali N. V
Journal of Evolution of Medical and Dental Sciences. 2018; 7(39): 4268
[Pubmed] | [DOI]
10 Status of ESBL Producing Bacteria Isolated from Skin Wound at a Tertiary Care Hospital in Bangladesh
Taslima Yasmin,Md. Abdullah Yusuf,Mohammed Abdun Nur Sayam,Rezwana Haque,Golam Mowla
Advances in Infectious Diseases. 2015; 05(04): 174
[Pubmed] | [DOI]
11 The Bacterial Isolates and Plasmid Profile of Extended Spectrum Beta-Lactamases Producers Causing Urinary Tract Infection among Pregnant Women in Uyo, Nigeria
Ifeanyi Abraham Onwuezobe,Florence Effiong Orok
Journal of Biosciences and Medicines. 2015; 03(07): 25
[Pubmed] | [DOI]
12 Emergence of coryneform bacteria as pathogens in nosocomial surgical site infections in a tertiary care hospital of North India
Meher Rizvi,Mehnaz Waris Rizvi,Mehnaz Waris Shaheen,Asfia Sultan,Fatima Khan,Indu Shukla,Abida Malik
Journal of Infection and Public Health. 2013; 6(4): 283
[Pubmed] | [DOI]
13 Extended-spectrum  -lactamase/AmpC-producing uropathogenic Escherichia coli from HIV patients: do they have a low virulence score?
K. Padmavathy,K. Padma,S. Rajasekaran
Journal of Medical Microbiology. 2013; 62(Pt_3): 345
[Pubmed] | [DOI]
14 Frequency and Characteristics of Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Organisms in Neonates: A Prospective Cohort Study
Nandini Vijayakanthi,Dheeraj Bahl,Nirmaljit Kaur,Arti Maria,Nand Kishore Dubey
BioMed Research International. 2013; 2013: 1
[Pubmed] | [DOI]
15 Frequency of beta lactamase enzyme in isolated pathogen bacteria from hospital in-vivo and in-vitro condition
Jalalpoor, S.
Journal of Isfahan Medical School. 2011; 29(131)
16 Extended spectrum β-lactamase producing Enterobacteriaceae & antibiotic co-resistance
Rudresh, S.M., Nagarathnamma, T.
Indian Journal of Medical Research. 2011; 133(1): 116-118
17 Prevalence of extended spectrum beta lactamase producing Enterobacteriaceae in clinical specimens
Ravi, G.S., Krishna, B.V.S., Nandihal, N.W., Patil, A.B., Chandrasekhar, M.R.
Biomedicine. 2011; 31(1): 78-83
18 A pharmacokinetic drug interaction study of ceftazidime with clavulanic acid in healthy male Indian subjects
Manoj Singh Tomar, Anil Kumar Patni, Rachna Arora, Nageshwar Rao Thudi, Vikesh Kumar Shrivastav, Sunil Iyer, Arshad Hussain Khuroo, Sachin Mehra, Tausif Monif
Clinical Research and Regulatory Affairs. 2011; 28(2): 49
[VIEW] | [DOI]
19 Antibiotic susceptibility of intra-abdominal infection isolates from Indian hospitals during 2008
S. P. Hawser, R. E. Badal, S. K. Bouchillon, D. J. Hoban
Journal of Medical Microbiology. 2010; 59(9): 1050
[VIEW] | [DOI]
20 Prevalence of the TEM, SHV and CTX-M families of extended-spectrum β-lactamases in Escherichia coli and Klebsiella spp at the University Hospital of Santa Maria, State of Rio Grande do Sul | [Prevalęncia das famílias TEM, SHV e CTX-M de β-lactamases de espectro estendido em Escherichia coli e Klebsiella spp no Hospital Universitário de Santa Maria, Estado do Rio Grande do Sul]
De Oliveira, C.F., Dal Forno, N.L.F., Alves, I.A., Horta, J.A., Rieger, A., Alves, S.H.
Revista da Sociedade Brasileira de Medicina Tropical. 2009; 42(5): 556-560
21 β-lactamase producing Acinetobacter species in hospitalized patients
Kansal, R., Pandey, A., Asthana, A.K.
Indian Journal of Pathology and Microbiology. 2009; 52(3): 456-457
22 Prevalęncia das famílias TEM, SHV e CTX-M de ß-lactamases de espectro estendido em Escherichia coli e Klebsiella spp no Hospital Universitário de Santa Maria, Estado do Rio Grande do Sul
Caio Fernando de Oliveira,Nara Lucia Frazzon Dal Forno,Izabel Almeida Alves,Jorge André Horta,Alexandre Rieger,Sydney Hartz Alves
Revista da Sociedade Brasileira de Medicina Tropical. 2009; 42(5): 556
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Email Alert *
    Add to My List *
* Registration required (free)  

    Materials and Me...
    Article Figures
    Article Tables

 Article Access Statistics
    PDF Downloaded1024    
    Comments [Add]    
    Cited by others 22    

Recommend this journal